<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04206501</url>
  </required_header>
  <id_info>
    <org_study_id>00003638</org_study_id>
    <nct_id>NCT04206501</nct_id>
  </id_info>
  <brief_title>OptiVol for Precision Medical Management of Heart Failure</brief_title>
  <acronym>(OPTIMED-HF)</acronym>
  <official_title>OptiVol for Precision Medical Management of Heart Failure</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Rochester</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Medtronic</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Rochester</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This clinical study is designed to show that a multidisciplinary team following a
      pre-specified standard of care medication decision model based on data from an implanted
      cardioverter device will increase the rate of change in Guideline Directed Medical Therapy
      (GDMT) in the intervention group compared to the conventional group in patients with ischemic
      and non-ischemic cardiomyopathies.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Subjects in this study will be randomized (2:1) to an intervention group whose medical care
      will be guided by data from a cardiac implantable electronic device (CIED) including
      information on heart rate, activity, and fluid status derived from the OptiVol monitor versus
      a conventional management control group. Subjects will followed for 12 months with follow up
      contact for 6 consecutive months and a chart review at 12 months. The study population will
      include patients with ischemic and non-ischemic cardiomyopathy who have had an ICD implanted
      per standard of care guidelines.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 5, 2020</start_date>
  <completion_date type="Anticipated">January 2022</completion_date>
  <primary_completion_date type="Anticipated">September 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The primary outcome of this study is the rate of change in medical management with beta-blockers, diuretics and sacubitril/Valsartan (defined as initiation, termination, switch, or dosing adjustment) in the intervention group compared to usual care</measure>
    <time_frame>6 Months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Recurrent changes to medication type reflecting ongoing personalized optimization.</measure>
    <time_frame>6 month</time_frame>
    <description>Frequency of change in medication type.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Recurrent changes to medication dosing reflecting ongoing personalized optimization.</measure>
    <time_frame>6 month</time_frame>
    <description>Frequency of change in medication dose.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean changes in functional status (measured by 6-minute walk distance) in the intervention vs. control groups.</measure>
    <time_frame>6 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage change in average daily activity level. This will be measure using an accelerometer which will measure movement by degree and duration of motion.</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life (measured by Kansas City Cardiomyopathy Questionnaire) in the intervention vs. control groups.</measure>
    <time_frame>6 months</time_frame>
    <description>This consists of 15 questions that refer to heart failure and how it may affect a patients life. the scale is 0-100 with 0 meaning worse.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Healthcare utilization as determined by the number of unplanned office visits and hospitalizations in each group.</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Cardiac hospitalizations</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All-cause mortality</measure>
    <time_frame>12 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Laboratory Biomarkers (BNP-brain natriuretic peptide)</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Ischemic and Non-ischemic Cardiomyopathy</condition>
  <arm_group>
    <arm_group_label>ICM guided Medical Management Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A pre-specified management regimen based on standard clinical practice will be provided to the study team in which medical management including medication dosing (focusing on beta-blockers and diuretics) will be monitored and modified using Cardiac Implantable Electronic Devices (CIED) and OptiVol Monitor data. Based on CIED and patient engagement data, the study team will adjust medications and dosages, and optimize activity/exercise steps.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Conventional Management Control Group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Non-study physicians will receive CIED/OptiVol data (as in usual care) and its use and the management strategy will be left to his/her discretion. To control for patient contact, patients in the conventional management group will have the same study visits as the interventional group and will include in-person device interrogation, and documentation of any medications changes.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Medtronic ICD with Opti Vol-Monitor</intervention_name>
    <description>Physiologic and functional data from Cardiac Implantable Electronic Devices (CIEDs), including information on heart rate, activity, and fluid status derived from the OptiVol monitor, together with a concurrent patient engagement strategy through remote interactions, can be used to optimize the medical management of HF patients implanted with an ICD.</description>
    <arm_group_label>ICM guided Medical Management Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18 to 85 years of age on the date of randomization

          -  ICD implantation per guidelines for primary prevention in patients with ischemic and
             non-ischemic cardiomyopathy â‰¥3 calendar months ago.

          -  LVEF &lt;=35% on echocardiography within preceding 12 calendar months.

          -  SMART Phone or tablet with Bluetooth capability with internet access.

          -  No other identifiable reversible cause explaining the left ventricular dysfunction

        Exclusion Criteria:

          -  CRT implanted

          -  Medtronic device generator and/or device components not implanted

          -  Unstable clinical condition, life threatening arrhythmia

          -  Heart failure hospitalization within the preceding 3 calendar months

          -  Cognitive impairment

          -  Severe renal dysfunction (eGFR &lt; 30 ml/min/m2)

          -  Serious known concomitant disease with a lift expectancy of &lt; 12 calendar months

          -  Non-ambulatory NYHA class IV

          -  Pregnancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Spencer Z Rosero, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Rochester</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Shelley L Secor-Socha, MS</last_name>
    <phone>5852755384</phone>
    <email>shelley.secor-socha@heart.rochester.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Mary Brown, MS, RN</last_name>
    <phone>585-275-8823</phone>
    <email>mary.brown@heart.rochester.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Rochester Medical Center</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14642</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hanna Kopin</last_name>
      <phone>585-273-5247</phone>
      <email>hanna_kopin@urmc.rochester.edu</email>
    </contact>
    <investigator>
      <last_name>Spencer Rosero, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>O'Connor CM, Whellan DJ, Lee KL, Keteyian SJ, Cooper LS, Ellis SJ, Leifer ES, Kraus WE, Kitzman DW, Blumenthal JA, Rendall DS, Miller NH, Fleg JL, Schulman KA, McKelvie RS, Zannad F, PiÃ±a IL; HF-ACTION Investigators. Efficacy and safety of exercise training in patients with chronic heart failure: HF-ACTION randomized controlled trial. JAMA. 2009 Apr 8;301(14):1439-50. doi: 10.1001/jama.2009.454.</citation>
    <PMID>19351941</PMID>
  </reference>
  <reference>
    <citation>Roth GA, Poole JE, Zaha R, Zhou W, Skinner J, Morden NE. Use of Guideline-Directed Medications for Heart Failure Before Cardioverter-Defibrillator Implantation. J Am Coll Cardiol. 2016 Mar 8;67(9):1062-1069. doi: 10.1016/j.jacc.2015.12.046.</citation>
    <PMID>26940927</PMID>
  </reference>
  <reference>
    <citation>Hibbard JH, Greene J. What the evidence shows about patient activation: better health outcomes and care experiences; fewer data on costs. Health Aff (Millwood). 2013 Feb;32(2):207-14. doi: 10.1377/hlthaff.2012.1061. Review.</citation>
    <PMID>23381511</PMID>
  </reference>
  <reference>
    <citation>Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr, Drazner MH, Fonarow GC, Geraci SA, Horwich T, Januzzi JL, Johnson MR, Kasper EK, Levy WC, Masoudi FA, McBride PE, McMurray JJ, Mitchell JE, Peterson PN, Riegel B, Sam F, Stevenson LW, Tang WH, Tsai EJ, Wilkoff BL; American College of Cardiology Foundation; American Heart Association Task Force on Practice Guidelines. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2013 Oct 15;62(16):e147-239. doi: 10.1016/j.jacc.2013.05.019. Epub 2013 Jun 5.</citation>
    <PMID>23747642</PMID>
  </reference>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>December 10, 2019</study_first_submitted>
  <study_first_submitted_qc>December 18, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 20, 2019</study_first_posted>
  <last_update_submitted>March 5, 2020</last_update_submitted>
  <last_update_submitted_qc>March 5, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Rochester</investigator_affiliation>
    <investigator_full_name>Spencer Rosero, MD</investigator_full_name>
    <investigator_title>Professor Medicine M&amp;D-Cardiology Div</investigator_title>
  </responsible_party>
  <keyword>ICD</keyword>
  <keyword>OptiVol-Monitor</keyword>
  <keyword>Cardiac Compass</keyword>
  <keyword>Garmin Vivo Smart</keyword>
  <keyword>Guideline Directed Medical Therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
    <mesh_term>Cardiomyopathies</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

